Table 1 Comparison of clinical data between AGI group and N-AGI group in pDOC patients
Group | AGI group (n = 91) | N-AGI group (n = 74) | χ2/t/Z value | P value |
|---|---|---|---|---|
Number of cases | 91 | 74 | ||
Male (%) | 62 (68.13) | 44 (59.46) | 1.336 | 0.25 |
Age (X ± S) | 61.58 ± 12.21 | 58.74 ± 13.48 | 1.417 | 0.16 |
Causative disease of pDOC | ||||
TBI | 14 (15.38) | 20 (27.03) | 3.381 | 0.07 |
Intracerebral hemorrhage | 52 (57.14) | 44 (59.46) | 0.09 | 0.76 |
Cerebral infarction | 11 (12.09) | 3 (4.05) | 3.392 | 0.07 |
Ischemic hypoxic encephalopathy | 14 (15.38) | 7 (9.46) | 1.290 | 0.26 |
CRS-R score [M(QL, QU)] | 4 (2, 5) | 5 (4, 8) | 4.277 | < 0.01 |
SOFA score [ M(QL, QU)] | 3 (3, 4) | 3 (2, 3) | -5.744 | < 0.01 |
Use of broad-spectrum antibiotics (Number of cases, %) | 65 (71.43) | 42 (56.76) | 3.854 | 0.05 |
Multidrug-resistant bacterial infection (Number of cases, %) | 35 (38.46) | 28 (37.84) | 0.007 | 0.94 |
Mechanical Ventilation (Number of cases, %) | 11 (12.09) | 5 (6.76) | 1.325 | 0.25 |
Use of vasoactive drugs (Number of cases, %) | 11 (12.09) | 0 (0) | 9.584 | < 0.01 |
Use of sedatives (Number of cases, %) | 35 (38.46) | 26 (35.14) | 0.194 | 0.66 |
Use of analgesics (Number of cases, %) | 1 (1.09) | 0 (0) | 0.818 | 0.37 |
WBC (× 109, \(\overline{\mathrm{X} }\)±S) | 8.49 ± 2.96 | 7.41 ± 2.45 | 2.557 | 0.01 |
Neutrophil percentage (%, X ± S) | 69.56 ± 10.49 | 67.22 ± 9.44 | 1.492 | 0.14 |
Lymphocyte count (× 109, \(\overline{\mathrm{X} }\)±S) | 1.55 ± 0.75 | 1.62 ± 0.62 | -0.623 | 0.53 |
Hemoglobin (g/l, \(\overline{\mathrm{X} }\)±S) | 107.22 ± 19.03 | 112.02 ± 18.19 | -1.643 | 0.10 |
Platelets (× 109, \(\overline{\mathrm{X} }\)±S) | 260.31 ± 98.44 | 258.59 ± 92.33 | 0.115 | 0.91 |
CRP, [mg/L, M(QL, QU)] | 16.96 (6.58, 46.33) | 9.08 (4.77, 22.00) | -2.770 | < 0.01 |
SAA (mg/l, \(\overline{\mathrm{X} }\)±S) | 87.44 ± 108.64 | 44.20 ± 66.67 | 3.127 | < 0.01 |
PCT (ng/l, \(\overline{\mathrm{X} }\)±S) | 0.51 ± 0.60 | 0.14 ± 0.17 | 5.596 | < 0.01 |
Prothrombin time (s, \(\overline{\mathrm{X} }\)±S) | 13.22 ± 1.21 | 12.95 ± 0.97 | 1.522 | 0.13 |
Activated partial thromboplastin time (s, \(\overline{\mathrm{X} }\)±S) | 35.94 ± 7.18 | 35.12 ± 5.46 | 0.805 | 0.42 |
D-dimer (μg/mL, \(\overline{\mathrm{X} }\)±S) | 2.90 ± 4.19 | 1.53 ± 1.83 | 2.802 | < 0.01 |
Serum potassium [mmol/L, M (QL, QU)] | 4.11 (3.77, 4.37) | 3.92 (3.63, 4.22) | -2.312 | 0.02 |
ALB [g/L, M(QL, QU)] | 33.1 (30.6, 36.6) | 35.05 (32.48, 38.68) | 2.865 | < 0.01 |
Aspartate aminotransferase (U/L, \(\overline{\mathrm{X} }\)±S) | 40.33 ± 33.18 | 31.73 ± 28.32 | 1.796 | 0.07 |
Alanine aminotransferase (U/L, \(\overline{\mathrm{X} }\)±S) | 49.48 ± 70.17 | 35.39 ± 40.04 | 1.536 | 0.13 |
Blood urea nitrogen (mmol/L, \(\overline{\mathrm{X} }\)±S) | 6.90 ± 5.41 | 4.82 ± 1.97 | 3.405 | < 0.01 |
Creatinine (μmol/L, \(\overline{\mathrm{X} }\)±S) | 54.57 ± 37.07 | 45.20 ± 16.00 | -2.173 | 0.03 |
Total bilirubin (μmol/L, \(\overline{\mathrm{X} }\)±S) | 11.17 ± 5.04 | 11.43 ± 4.51 | -0.349 | 0.73 |
Direct bilirubin (μmol/L, \(\overline{\mathrm{X} }\)±S) | 3.91 ± 3.83 | 3.19 ± 1.40 | 1.649 | 0.10 |
Indirect bilirubin (μmol/L, \(\overline{\mathrm{X} }\)±S) | 7.62 ± 3.73 | 8.24 ± 3.45 | -1.093 | 0.28 |
Lactate dehydrogenase (U/L, \(\overline{\mathrm{X} }\)±S) | 236.35 ± 90.24 | 197.35 ± 57.88 | 3.360 | < 0.01 |
Triglycerides [mmol/L, M(QL, QU)] | 1.47 (1.17, 2.11) | 1.52 (1.14, 2.00) | -0.182 | 0.86 |
Cholesterol [mmol/L, M(QL, QU)] | 4.10 (3.41, 4.70) | 4.26 (3.56, 5.18) | 1.407 | 0.16 |
Prealbumin [mg/L, M(QL, QU)] | 191.5 (153.00, 236.90) | 200.50 (150.80, 246.03) | 0.473 | 0.64 |
Anticoagulant therapy (Number of cases, %) | 30 (32.97) | 22 (29.73) | 0.198 | 0.66 |
IFABP (μgl/L, \(\overline{\mathrm{X} }\)±S) | 19.11 ± 3.77 | 17.57 ± 2.45 | 3.181 | < 0.01 |
DAO (mmol/L, \(\overline{\mathrm{X} }\)±S) | 1.99 ± 0.53 | 1.43 ± 0.32 | 8.248 | < 0.01 |